Lorlatinib experience in a patient with ALK + non-small cell lung cancer on hemodialysis: A case report.
Ali Fuat GürbüzMelek Karakurt EryilmazOğuzhan YıldızBahattin Engin KayaMurat ArazMustafa YıldırımPublished in: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2024)
We presented our experience using lorlatinib in a patient with metastatic ALK + NSCLC undergoing hemodialysis. Although the dosage of lorlatinib in hemodialysis patients is still controversial, our case report indicates that 100 mg lorlatinib was safe in this patient.